Related Experiment Videos
Turnover of exogenous artificial surfactant
M R Ashton1, A D Postle, M A Hall
1Department of Child Health, University of Southampton.
Archives of Disease in Childhood
|April 1, 1992
Summary
Artificial surfactant Exosurf alters infant lung fluid composition for over a week. Adjusting Exosurf dosage may optimize treatment for respiratory distress syndrome, requiring further clinical evaluation.
Area of Science:
- Neonatal Medicine
- Pulmonary Medicine
- Biochemistry
Background:
- Respiratory distress syndrome (RDS) is a common neonatal condition.
- Artificial surfactants are used to manage RDS.
- Understanding surfactant turnover is crucial for optimizing treatment.
Purpose of the Study:
- To investigate the pharmacokinetic profile of artificial surfactant Exosurf in infants with RDS.
- To analyze changes in lung surfactant composition following Exosurf administration.
- To evaluate the impact of different Exosurf dosing regimens on surfactant turnover.
Main Methods:
- High-performance liquid chromatography (HPLC) was employed to analyze phosphatidylcholine (PC) composition.
- Endotracheal tube secretions were collected serially from three infant groups: two doses/24h, four doses/36h, and controls.
- Key parameters analyzed included % dipalmitoylphosphatidylcholine (% DPPC) and the DPPC:palmitoyloleoylphosphatidylcholine (POPC) ratio.
Main Results:
- Exosurf administration significantly altered endotracheal aspirate PC composition for over one week.
- A four-dose regimen (36 hours) showed a trend towards prolonged persistence of these alterations compared to a two-dose regimen (24 hours).
- Observed changes in % DPPC and DPPC:POPC ratio indicate Exosurf's impact on lung surfactant composition.
Conclusions:
- Exosurf significantly impacts lung surfactant composition in infants with RDS.
- The duration of Exosurf-induced compositional changes may be dose-dependent.
- Further clinical studies are needed to determine optimal Exosurf dosing strategies for RDS management.